- RESEARCH USE ONLY
- INDEPENDENTLY THIRD-PARTY TESTED
- COA EVERY LOT
- US-BASED OPERATIONS
| Specification | Details |
|---|---|
| Compound | PT-141 |
| Alternative Name | Bremelanotide |
| Type | Synthetic cyclic heptapeptide |
| Sequence | Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys |
| Quantity | 10 mg |
| Purity | ≥99% HPLC Certified |
| Molecular Formula | C₅₀H₆₈N₁₄O₁₀ |
| Molecular Weight | 1025.2 g/mol |
| CAS Number | 189691-06-3 |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Solubility | Soluble in laboratory-grade sterile water |
| Documentation | COA included in product image gallery |
$68.99
For Research Use Only | Not for Human or Veterinary Use
PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide and melanocortin receptor agonist. Its structure contains seven amino acid residues and includes a lactam bridge that gives the molecule its cyclic configuration. Research has examined its interaction with melanocortin receptor subtypes, including MC3R and MC4R.
This material is supplied as a lyophilized powder for laboratory research, analytical testing, and related scientific applications.
The listed molecular formula, molecular weight, CAS number, and sequence correspond to the PT-141 free-base/bremelanotide record in PubChem. The acetate form is chemically distinct and has a molecular weight of approximately 1043.2 g/mol, so the batch COA should be used to confirm the exact material form.
PT-141 is a cyclic peptide derived from the melanocortin peptide research field. Its structure includes N-acetyl-norleucine, an aspartic acid residue, histidine, D-phenylalanine, arginine, tryptophan, and lysine, with cyclization through a lactam linkage.
Experimental pharmacology has characterized bremelanotide as a melanocortin receptor agonist. Research has examined activity across several melanocortin receptor subtypes, with MC3R and MC4R among the receptors relevant to its pharmacological profile.
For laboratory research, PT-141 provides a defined cyclic peptide structure for analytical, receptor-binding, and pharmacological investigations involving melanocortin signaling.
The supplied material is specified at ≥99% HPLC Certified purity, with a Certificate of Analysis included in the product image gallery.
Researchers should review the applicable batch-specific COA for the reported purity, chemical form, and analytical information before incorporating the material into laboratory workflows.
Bremelanotide has a documented pharmaceutical history in the United States. FDA labeling identifies Vyleesi (bremelanotide injection) as an FDA-approved melanocortin receptor agonist, with initial U.S. approval in 2019 for a specific indication in premenopausal women. The FDA label also states that the approved product is not indicated for enhancing sexual performance.
That approval applies to the specific FDA-approved drug product and formulation. It does not mean that every research-grade PT-141 material is equivalent to the approved pharmaceutical product. The material described on this page is supplied strictly for laboratory research and analytical applications.
PT-141 is the original investigational code associated with bremelanotide, a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist.
PT-141 contains seven amino acid residues, making it a heptapeptide. Its defined sequence is Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys.
PT-141 contains an internal lactam linkage that connects residues within the peptide chain and produces its cyclic structure. This structural feature distinguishes it from a simple linear peptide.
Bremelanotide has been characterized as an agonist at multiple melanocortin receptor subtypes. Its pharmacological profile includes activity at MC1R, MC3R, MC4R, MC5R, and MC2R, with varying receptor potency.
The molecular weight of the PT-141 free-base form listed by PubChem is approximately 1025.2 g/mol. The acetate form has a different molecular weight, approximately 1043.2 g/mol.
Yes. PT-141 is an investigational name/synonym for bremelanotide, and PubChem lists both names for the same active molecular structure. The name bremelanotide is now used for the approved pharmaceutical active ingredient.
PT-141 is supplied as a laboratory research material with HPLC-certified purity and batch-specific documentation available through the product gallery.
For Research Use Only | Not for Human or Veterinary Use
